Search Results

There are 4324 results for: content related to: Symptomatic effect of selegiline in de novo parkinsonian patients

  1. Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules

    The Journal of Clinical Pharmacology

    Volume 47, Issue 10, October 2007, Pages: 1256–1267, Dr Albert J. Azzaro, Dr John Ziemniak, Ms Eva Kemper, Dr Bryan J. Campbell and Dr Chad VanDenBerg

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007304779

  2. A review of the pharmacology of selegiline

    Acta Neurologica Scandinavica

    Volume 84, Issue S136, October 1991, Pages: 44–59, E. H. Heinonen and R. Lammintausta

    Version of Record online : 29 JAN 2009, DOI: 10.1111/j.1600-0404.1991.tb05020.x

  3. SELEDO: a 5-y-ear long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa

    European Journal of Neurology

    Volume 6, Issue 2, March 1999, Pages: 141–150, H. Przuntek, B. Conrad, J. Dichgans, P.H. Kraus, P. Krauseneck, G. Pergande, U. Rinne, K. Schimrigk, J. Schnitker and H.P. Vogel

    Version of Record online : 27 JUL 2007, DOI: 10.1111/j.1468-1331.1999.tb00007.x

  4. Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications

    The Journal of Clinical Pharmacology

    Volume 47, Issue 2, February 2007, Pages: 146–158, Dr Albert J. Azzaro, Dr John Ziemniak, Ms Eva Kemper, Dr Bryan J. Campbell and Dr Chad VanDenBerg

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270006296151

  5. TOXICOKINETIC EVALUATION OF A SELEGILINE TRANSDERMAL SYSTEM IN THE DOG

    Biopharmaceutics & Drug Disposition

    Volume 18, Issue 2, March 1997, Pages: 165–184, JEFFREY S. BARRETT, ANTHONY R. DISANTO, PETER J. THOMFORD, ERIC M. LARSEN, MATTHEW J. PALAZZOLO and RICHARD J. MORALES

    Version of Record online : 4 DEC 1998, DOI: 10.1002/(SICI)1099-081X(199703)18:2<165::AID-BDD14>3.0.CO;2-S

  6. The pharmacokinetics and absolute bioavailability of selegiline in the dog

    Biopharmaceutics & Drug Disposition

    Volume 15, Issue 8, November 1994, Pages: 653–664, Iftekhar Mahmood, David K. Peters and William D. Mason

    Version of Record online : 8 FEB 2006, DOI: 10.1002/bdd.2510150804

  7. Selegiline in the treatment of Parkinson's disease

    Acta Neurologica Scandinavica

    Volume 80, Issue s126, November 1989, Pages: 103–111, Heinonen E H and Rinne U K

    Version of Record online : 29 JAN 2009, DOI: 10.1111/j.1600-0404.1989.tb01789.x

  8. MAO-B inhibitors for the treatment of Parkinson's disease

    Movement Disorders

    Volume 17, Issue S4, July/August 2002, Pages: S38–S44,

    Version of Record online : 29 JUL 2002, DOI: 10.1002/mds.5559

  9. Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans

    The Journal of Clinical Pharmacology

    Volume 37, Issue 7, July 1997, Pages: 602–609, Dr. Esa H. Heinonen, Mr. Markku I. Anttila, Mr. Hari L. Karnani, Ms. Leena M. Nyman, Mr. Jouni A. Vuorinen, Dr. Kaija A. Pyykkö and Dr. Risto A. S. Lammintausta

    Version of Record online : 8 MAR 2013, DOI: 10.1002/j.1552-4604.1997.tb04342.x

  10. Selegiline as the primary treatment of Parkinson's disease — a long-term double-blind study

    Acta Neurologica Scandinavica

    Volume 95, Issue 4, April 1997, Pages: 211–218, V. V. Myllylä, K. A. Sotaniemi, P. Hakulinen, O. Mäki-lkola and E. H. Heinonen

    Version of Record online : 29 JAN 2009, DOI: 10.1111/j.1600-0404.1997.tb00101.x

  11. Evaluation of the Potential for Pharmacodynamic and Pharmacokinetic Drug Interactions Between Selegiline Transdermal System and Two Sympathomimetic Agents (Pseudoephedrine and Phenylpropanolamine) in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 47, Issue 8, August 2007, Pages: 978–990, Dr. Albert J. Azzaro, Dr. Chad M. VanDenBerg, Dr. John Ziemniak, Ms Eva M. Kemper, Dr. Lawrence F. Blob and Dr. Bryan J. Campbell

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007302950

  12. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: Differing response in relation to presynaptic dopaminergic dysfunction

    Synapse

    Volume 27, Issue 4, December 1997, Pages: 336–346, Hanna M. Ruottinen, Juha O. Rinne, Vesa J. Oikonen, Jörgen R. Bergman, Merja T. Haaparanta, Olof H. Solin, Ulla H. Ruotsalainen and Urpo K. Rinne

    Version of Record online : 7 DEC 1998, DOI: 10.1002/(SICI)1098-2396(199712)27:4<336::AID-SYN7>3.0.CO;2-D

  13. You have free access to this content
    Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease

    British Journal of Clinical Pharmacology

    Volume 74, Issue 2, August 2012, Pages: 284–295, Thuy C. Vu, John G. Nutt and Nicholas H. G. Holford

    Version of Record online : 10 JUL 2012, DOI: 10.1111/j.1365-2125.2012.04208.x

  14. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites

    Clinical Pharmacology & Therapeutics

    Volume 56, Issue S6, December 1994, Pages: 742–749, Esa H Heinonen, Markku I Anttila and Risto A S Lammintausta

    Version of Record online : 19 DEC 1994, DOI: 10.1038/clpt.1994.204

  15. Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 12P2, December 2007, Pages: 174S–185S, Dr. Hubert H. Fernandez and Dr. Jack J. Chen

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.27.12part2.174S

  16. Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease — an interim analysis

    Acta Neurologica Scandinavica

    Volume 80, Issue s126, November 1989, Pages: 119–125, P. F. Teychenne and S. Parker

    Version of Record online : 29 JAN 2009, DOI: 10.1111/j.1600-0404.1989.tb01791.x

  17. CYP2D6 polymorphism is not crucial for the disposition of selegiline

    Clinical Pharmacology & Therapeutics

    Volume 64, Issue 4, October 1998, Pages: 402–411, Harry Scheinin, Markku Anttila, Marja-Liisa Dahl, Hari Karnani, Leena Nyman, Päivi Taavitsainen, Olavi Pelkonen and Leif Bertilsson

    Version of Record online : 16 OCT 1998, DOI: 10.1016/S0009-9236(98)90071-6

  18. Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers

    Biopharmaceutics & Drug Disposition

    Volume 16, Issue 7, October 1995, Pages: 535–545, Iftekhar Mahmood, Jacqueline S. Marinac, Sandra Willsie and William D. Mason

    Version of Record online : 11 JAN 2006, DOI: 10.1002/bdd.2510160703

  19. Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 46, Issue 8, August 2006, Pages: 933–944, Dr Albert J. Azzaro, Dr Chad M. VanDenBerg, Dr Lawrence F. Blob, Ms Eva M. Kemper, Dr Melvin Sharoky, Dr Dan A. Oren and Dr Bryan J. Campbell

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006289852

  20. Pharmacokinetics and metabolism of selegiline

    Acta Neurologica Scandinavica

    Volume 80, Issue s126, November 1989, Pages: 93–99, Heinonen E H, Myllylä V, Sotaniemi K, Lammintausta R, Salonen J S, Anttila M, Savijärvi M, Kotila M and Rinne U K

    Version of Record online : 29 JAN 2009, DOI: 10.1111/j.1600-0404.1989.tb01788.x